Clinical implications of food–drug interactions with small-molecule kinase inhibitors
The Lancet Oncology , Volume 21 - Issue 5 p. e265- e279
During the past two decades, small-molecule kinase inhibitors have proven to be valuable in the treatment of solid and haematological tumours. However, because of their oral administration, the intrapatient and interpatient exposure to small-molecule kinase inhibitors (SMKIs) is highly variable and is affected by many factors, such as concomitant use of food and herbs. Food–drug interactions are capable of altering the systemic bioavailability and pharmacokinetics of these drugs. The most important mechanisms underlying food–drug interactions are gastrointestinal drug absorption and hepatic metabolism through cytochrome P450 isoenzymes. As food–drug interactions can lead to therapy failure or severe toxicity, knowledge of these interactions is essential. This Review provides a comprehensive overview of published studies involving food–drug interactions and herb–drug interactions for all registered SMKIs up to Oct 1, 2019. We critically discuss US Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidelines concerning food-drug interactions and offer clear recommendations for their management in clinical practice.
|The Lancet Oncology|
|Organisation||Department of Medical Oncology|
Veerman, G.D.M, Hussaarts, K.G.A.M, Jansman, F.G.A, Koolen, S.L.W, van Leeuwen, R.W.F, & Mathijssen, A.H.J. (2020). Clinical implications of food–drug interactions with small-molecule kinase inhibitors. The Lancet Oncology (Vol. 21, pp. e265–e279). doi:10.1016/S1470-2045(20)30069-3